Status:
COMPLETED
Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Astellas Pharma Europe B.V.
Conditions:
Asthma, Bronchial
Bronchial Asthma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.
Eligibility Criteria
Inclusion
- Diagnosis of asthma
- Patients treated with inhaled corticosteroid and long acting beta 2 agonist
- FEV1(forced expiratory volume in 1 second)\>50% to 80%
Exclusion
- Respiratory infection within 2weeks
- Asthma exacerbation within 6 weeks
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2005
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00189722
End Date
July 1 2005
Last Update
April 17 2008
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Brno, Czechia, 65691
2
Krhanice, Czechia, 25742
3
Olomouc, Czechia, 77520
4
Šumperk, Czechia, 78752